Vatelizumab
Appearance
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Humanized |
Target | integrin alpha 2 |
Clinical data | |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
(what is this?) (verify) |
Vatelizumab is an immunomodulator. It binds to integrin alpha 2.[1]
It was withdrawn from Phase II trials for inflammatory bowel disease due to a lack of efficacy.[2]
References
- ^ World Health Organization (2011). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 105" (PDF). WHO Drug Information. 25 (2).
- ^ Mozaffari S, Nikfar S, Abdollahi M (2015). "Inflammatory bowel disease therapies discontinued between 2009 and 2014". Expert Opin Investig Drugs. 24 (7): 949–56. doi:10.1517/13543784.2015.1035432. PMID 25861835.